Archive

What Melanotan II is, how its activation of all five melanocortin receptors produces tanning, libido enhancement, and appetite suppression through distinct receptor pathways, why it led directly to the development of FDA-approved PT-141, and what the side effect profile including the nevi concern means for who should and should not consider it

What LL-37 is, how its membrane-disrupting mechanism differs from conventional antibiotics and why bacteria cannot easily develop resistance to it, what biofilm disruption means for chronic infections, and how its wound healing and immune modulating properties extend its applications well beyond direct pathogen killing.

What the Phase 2 signal showed, why the Phase 3 failure matters and cannot be rationalized away, what the mechanistic argument for AOD-9604 actually supports, and how to think about a compound where the evidence does not resolve cleanly in either direction.

What changes about bioavailability, pharmacokinetics, and administration requirements when semaglutide and tirzepatide are delivered orally rather than by injection, who oral formulations are most appropriate for, and how to think about the decision between oral and injectable delivery.

What Thymosin Alpha-1 is, how immune modulation differs from immune stimulation, why decades of clinical use across hepatitis, cancer immunotherapy, and critical illness support its evidence base, and how its effects on T-cell maturation and senescent cell clearance connect it directly to the hallmarks of aging framework.